DE602005014849D1 - Imidazoä1,2-cüpyrimidinylessigsäurederivate - Google Patents

Imidazoä1,2-cüpyrimidinylessigsäurederivate

Info

Publication number
DE602005014849D1
DE602005014849D1 DE602005014849T DE602005014849T DE602005014849D1 DE 602005014849 D1 DE602005014849 D1 DE 602005014849D1 DE 602005014849 T DE602005014849 T DE 602005014849T DE 602005014849 T DE602005014849 T DE 602005014849T DE 602005014849 D1 DE602005014849 D1 DE 602005014849D1
Authority
DE
Germany
Prior art keywords
diseases
allergic
imidazo
acid derivative
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602005014849T
Other languages
English (en)
Inventor
Tai-Wei Ly
Takashi Yoshino
Yuki Takekawa
Takuya Shintani
Hiromi Sugimoto
Kevin B Bacon
Klaus Urbahns
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GB007 Inc
Original Assignee
Actimis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actimis Pharmaceuticals Inc filed Critical Actimis Pharmaceuticals Inc
Publication of DE602005014849D1 publication Critical patent/DE602005014849D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
DE602005014849T 2004-01-31 2005-01-19 Imidazoä1,2-cüpyrimidinylessigsäurederivate Active DE602005014849D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04002144 2004-01-31
PCT/EP2005/000475 WO2005073234A2 (en) 2004-01-31 2005-01-19 Imidazo[1,2-c]pyrimidinylacetic acid derivatives

Publications (1)

Publication Number Publication Date
DE602005014849D1 true DE602005014849D1 (de) 2009-07-23

Family

ID=34814234

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602005014849T Active DE602005014849D1 (de) 2004-01-31 2005-01-19 Imidazoä1,2-cüpyrimidinylessigsäurederivate

Country Status (24)

Country Link
US (1) US7750014B2 (de)
EP (1) EP1718649B1 (de)
JP (1) JP4996257B2 (de)
KR (1) KR101207428B1 (de)
CN (1) CN100584844C (de)
AT (1) ATE433452T1 (de)
AU (1) AU2005209381B2 (de)
BR (1) BRPI0507123A (de)
CA (1) CA2551778C (de)
CY (1) CY1109274T1 (de)
DE (1) DE602005014849D1 (de)
DK (1) DK1718649T3 (de)
ES (1) ES2326896T3 (de)
HK (1) HK1101969A1 (de)
IL (1) IL177083A (de)
MX (1) MXPA06007674A (de)
NO (1) NO20063878L (de)
NZ (1) NZ548396A (de)
PL (1) PL1718649T3 (de)
PT (1) PT1718649E (de)
RU (1) RU2373208C2 (de)
SI (1) SI1718649T1 (de)
WO (1) WO2005073234A2 (de)
ZA (1) ZA200605387B (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1833791E (pt) 2004-12-27 2011-10-19 Actelion Pharmaceuticals Ltd Derivados de 2,3,4,9-tetra-hidro-1h-carbazol como antgonistas do receptor crth2
ES2374321T3 (es) 2006-08-07 2012-02-15 Actelion Pharmaceuticals Ltd. Derivados del ácido (3-amino-1,2,3,4-tetrahidro-9h-carbazol-9-il)-acético.
JP2010523627A (ja) * 2007-04-13 2010-07-15 ノバルティス アーゲー Ｇｐｂａｒ１アゴニストとしてのピリダジン誘導体、ピリジン誘導体およびピラン誘導体
WO2008156780A1 (en) * 2007-06-21 2008-12-24 Actimis Pharmaceuticals, Inc. Particulates of a crth2 antagonist
RU2491279C2 (ru) * 2007-09-25 2013-08-27 Актимис Фармасьютикалз, Инк. 2-s-бензилзамещенные пиримидины в качестве антагонистов crth2
BRPI0817319A2 (pt) * 2007-09-25 2015-03-17 Actimis Pharmaceuticals Inc Composto, composição farmacêutica, e, método para tratamento ou profilaxia de uma doença ou condição ou um ou mais sintomas da mesma.
US8242145B2 (en) 2008-02-14 2012-08-14 Panmira Pharmaceuticals, Llc Cyclic diaryl ether compounds as antagonists of prostaglandin D2 receptors
US8426449B2 (en) 2008-04-02 2013-04-23 Panmira Pharmaceuticals, Llc Aminoalkylphenyl antagonists of prostaglandin D2 receptors
EP2328876B1 (de) 2008-09-02 2012-11-21 Actimis Pharmaceuticals, Inc., Isotopenangereicherte pyrimidin-5-ylessigsäurederivate als crth2-antagonisten
WO2010057118A2 (en) 2008-11-17 2010-05-20 Amira Pharmaceuticals, Inc. Heterocyclic antagonists of prostaglandin d2 receptors
RU2562255C2 (ru) 2010-03-22 2015-09-10 Актелион Фармасьютиклз Лтд Производные 3-(гетероариламино)-1,2,3,4-тетрагидро-9н-карбазола и их применение в качестве модуляторов рецепторов простагландина d2
TW201201805A (en) 2010-07-05 2012-01-16 Actelion Pharmaceuticals Ltd 1-phenyl-substituted heterocyclyl derivatives and their use as prostaglandin D2 receptor modulators
EP2590979A1 (de) 2010-07-09 2013-05-15 Bayer Intellectual Property GmbH Annellierte pyrimidine und triazine und ihre verwendung zur behandlung bzw. prophylaxe von herz-kreislauf-erkrankungen
DE102010031149A1 (de) 2010-07-09 2012-01-12 Bayer Schering Pharma Aktiengesellschaft Annellierte Pyrimidine und Triazine und ihre Verwendung
DE102011003315A1 (de) 2011-01-28 2012-08-02 Bayer Schering Pharma Aktiengesellschaft Annellierte Pyrimindine und Triazine und ihre Verwendung
WO2012051036A1 (en) 2010-10-11 2012-04-19 Merck Sharp & Dohme Corp. Quinazolinone-type compounds as crth2 antagonists
EP2457900A1 (de) 2010-11-25 2012-05-30 Almirall, S.A. Neue Pyrazolderivate mit CRTH2-antagonistischem Verhalten
KR101928595B1 (ko) 2011-04-14 2018-12-12 이도르시아 파마슈티컬스 리미티드 7-(헤테로아릴-아미노)-6,7,8,9-테트라히드로피리도［1,2-ａ］인돌 아세트산 유도체 및 프로스타글란딘 ｄ2 수용체 조절자로서의 이의 용도
AU2012351342A1 (en) 2011-12-16 2014-07-24 Atopix Therapeutics Limited Combination of CRTH2 antagonist and a proton pump inhibitor for the treatment of eosinophilic esophagitis
KR20140107550A (ko) 2011-12-21 2014-09-04 액테리온 파마슈티칼 리미티드 헤테로시클릴 유도체 및 프로스타글란딘 ｄ2 수용체 조절제로서의 그의 용도
DE102012200360A1 (de) 2012-01-11 2013-07-11 Bayer Intellectual Property Gmbh Substituierte Triazine und ihre Verwendung
DE102012200349A1 (de) 2012-01-11 2013-07-11 Bayer Intellectual Property Gmbh Substituierte annellierte Pyrimidine und Triazine und ihre Verwendung
CA2866213A1 (en) 2012-03-06 2013-09-12 Bayer Intellectual Property Gmbh Substituted azabicycles and use thereof
JP6127135B2 (ja) 2012-07-05 2017-05-10 アクテリオン ファーマシューティカルズ リミテッドＡｃｔｅｌｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ １−フェニル置換ヘテロシクリル誘導体及びプロスタグランジンｄ２受容体調節剤としてのそれらの使用
HUE039614T2 (hu) 2014-03-17 2019-01-28 Idorsia Pharmaceuticals Ltd Azaindol-ecetsav-származékok és prosztaglandin D2 receptor modulátorokként történõ alkalmazásuk
CA2938107A1 (en) 2014-03-18 2015-09-24 Actelion Pharmaceuticals Ltd Azaindole acetic acid derivatives and their use as prostaglandin d2 receptor modulators
UA123156C2 (uk) 2015-09-15 2021-02-24 Ідорсія Фармасьютікалз Лтд КРИСТАЛІЧНА ФОРМА (S)-2-(8-((5-ХЛОРПІРИМІДИН-2-ІЛ)(МЕТИЛ)АМІНО)-2-ФТОР-6,7,8,9-ТЕТРАГІДРО-5H-ПІРИДО[3,2-b]ІНДОЛ-5-ІЛ)ОЦТОВОЇ КИСЛОТИ, ЇЇ ЗАСТОСУВАННЯ ТА ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЇЇ МІСТИТЬ
KR20190103507A (ko) 2018-02-12 2019-09-05 김강민 지하철 혼잡도 알림 시스템
TW202100015A (zh) 2019-02-28 2021-01-01 瑞士商先正達農作物保護公司 具有含硫取代基之殺有害生物活性雜環衍生物
CN114681438B (zh) * 2022-05-17 2024-03-19 中国医学科学院基础医学研究所 二甲双胍及其它含胍化合物在逆转Gal-10结晶趋势并缓解相关疾病中应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE790679A (fr) 1971-11-03 1973-04-27 Ici Ltd Derives de l'indole
GB9125842D0 (en) 1991-12-04 1992-02-05 Ici Plc Heterocyclic derivatives
JP2001302667A (ja) * 2000-04-28 2001-10-31 Bayer Ag イミダゾピリミジン誘導体およびトリアゾロピリミジン誘導体
US6878522B2 (en) 2000-07-07 2005-04-12 Baiyong Li Methods for the identification of compounds useful for the treatment of disease states mediated by prostaglandin D2
EP1413306A1 (de) 2002-10-21 2004-04-28 Warner-Lambert Company LLC Tetrahydrochinolin-Derivate als CRTH2 Antagonisten
AU2003297398B2 (en) 2002-12-20 2009-09-24 Amgen Inc. Asthma and allergic inflammation modulators
ATE316077T1 (de) * 2003-04-25 2006-02-15 Actimis Pharmaceuticals Inc Pyrimidin-essigsäure derivate geeignet zur behandlung von crth2-bedingten krankheiten

Also Published As

Publication number Publication date
PT1718649E (pt) 2009-08-06
PL1718649T3 (pl) 2009-11-30
WO2005073234A2 (en) 2005-08-11
ZA200605387B (en) 2008-05-28
WO2005073234A3 (en) 2005-10-06
JP2007519659A (ja) 2007-07-19
NZ548396A (en) 2010-06-25
EP1718649A2 (de) 2006-11-08
CN1938310A (zh) 2007-03-28
SI1718649T1 (sl) 2009-10-31
BRPI0507123A (pt) 2007-06-19
DK1718649T3 (da) 2009-08-24
CA2551778C (en) 2013-10-22
RU2373208C2 (ru) 2009-11-20
JP4996257B2 (ja) 2012-08-08
US20090012102A1 (en) 2009-01-08
CN100584844C (zh) 2010-01-27
NO20063878L (no) 2006-10-11
HK1101969A1 (en) 2007-11-02
CA2551778A1 (en) 2005-08-11
ES2326896T3 (es) 2009-10-21
IL177083A (en) 2011-10-31
KR101207428B1 (ko) 2012-12-04
ATE433452T1 (de) 2009-06-15
EP1718649B1 (de) 2009-06-10
KR20060130187A (ko) 2006-12-18
MXPA06007674A (es) 2006-09-04
AU2005209381A1 (en) 2005-08-11
CY1109274T1 (el) 2014-07-02
US7750014B2 (en) 2010-07-06
RU2006131304A (ru) 2008-03-10
AU2005209381B2 (en) 2011-06-30
IL177083A0 (en) 2006-12-10

Similar Documents

Publication Publication Date Title
DK1718649T3 (da) Imidazo[1,2-c]pyrimidinyleddikesyrederivater
TW200505873A (en) Pyrimidine derivatives
EP2380891B1 (de) Substituierte Piperidino-Dihydrothienopyrimidine
WO2004011427A3 (en) Substituted benzanilides as modulators of the ccr5 receptor
TWI400234B (zh) 作為組織胺ｈ4受體調節劑之苯并咪唑-２-基嘧啶類及吡類
WO2004010943A3 (en) Substituted benzanilides as modulators of the ccr5 receptor
MXPA05010055A (es) Derivados de 2-fenoxi- y 2-fenil-sulfomamida con actividad antagonista del ccr3, para el tratamiento del asma y otros desordenes inflamatorios o inmunologicos.
JO3041B1 (ar) مركبات جديدة مفيدة لمعالجة الأمراض التنكسية والالتهابية
TW200716648A (en) Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia
BR0314830A (pt) Derivados de azol-pirimidina fundida
ATE424402T1 (de) Imidazopyridinverbindungen
ZA201100526B (en) Triazolo [4,5-d]pyramidine derivatives and their use as purine receptor antagonists
WO2010142766A3 (en) Pyrimidine derivatives as zap-70 inhibitors
NO20091489L (no) Tiazolpyrazolopyridiner som CRF1 reseptorantagonister
EA201170374A1 (ru) Производные замещенных трициклических кислот в качестве агонистов рецептора s1p1, применимые при лечении аутоиммунных и воспалительных заболеваний
WO2004010942A3 (en) Substituted heterocyclic compounds as modulators of the ccr5 receptor
JP2015517587A5 (de)
DE602006016244D1 (de) Diazaspiro-ä4,4ü-nonanderivate als neurokinin-(nk1)-antagonisten
Xia et al. Substituted dipiperidine alcohols as potent CCR2 antagonists
WO2005058898A3 (en) Purine compounds which can be used as phosphodiesterase (pde) type iv inhibitors
TW200640910A (en) Piperidinyl piperazine derivatives useful as inhibitors of chemokine receptors
DOP2004000844A (es) Derivados 2-fenoxi y 2-fenilsufonamida con actividad antagonista ccr3 para el tratamiento de asma y otros trastornos inflamatorios o inmunologicos
Hao et al. Human Bone Marrow Derived Mesenchymal Stem Cells And Their Released Microvesicles May Promote The Resolution Of Acute Lung Injury In Mice In Part Through Inhibition Of Multidrug Resistance-Associated Protein 1
Edwards et al. Benzoimidazol-2-yl pyrimidines and pyrazines as modulators of the histamine H4 receptor
JP2010173956A (ja) ピロール化合物を有効成分として含有するケモカイン産生阻害剤

Legal Events

Date Code Title Description
8364 No opposition during term of opposition